Literature DB >> 9598507

The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.

J Noldus1, M Graefen, E Huland, C Busch, P Hammerer, H Huland.   

Abstract

PURPOSE: We analyzed the use of the ratio of free-to-total prostate specific antigen (PSA), also termed percentage of free PSA, for predicting tumor stage, volume and grade in patients with clinically localized prostate cancer.
MATERIALS AND METHODS: A total of 515 consecutive patients underwent further prostate evaluation due to elevated PSA (greater than 4.0 ng./ml.) or abnormal digital rectal examination. Prostate cancer was diagnosed in 307 patients (59.6%), including 170 (55.4%) who underwent radical retropubic prostatectomy. Data on pathological stage, Gleason grade, and total and Gleason grade 4 cancer volume were available in all patients. In the remaining 208 men (40.4%) benign prostate hyperplasia was diagnosed. Total and free PSA was measured in preoperative serum.
RESULTS: Total PSA was significantly higher (p <0.0001) in the 71 men with stage pT3 tumors than in the 91 with pT2 disease. Eight patients had stage pT4 tumors. Cancer volume correlated well with advancing pathological stage (p <0.0001) and total PSA (p <0.0001). The free-to-total PSA ratio was not significantly different (p = 0.93) in stages pT2 and pT3 tumors, and it did not correlate with total (p = 0.71) or pure Gleason grade 4 (p = 0.94) cancer volume. However, the ratio of free-to-total PSA tended to decrease (p = 0.07) in tumors of increasing Gleason grade.
CONCLUSIONS: The ratio of free-to-total PSA does not help in the preoperative prediction of final tumor stage and volume. However, disease grading may alter the free-to-total PSA ratio.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9598507

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml.

Authors:  Lorenzo Masieri; Andrea Minervini; Gianni Vittori; Michele Lanciotti; Federico Lanzi; Alberto Lapini; Marco Carini; Sergio Serni
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

3.  The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.

Authors:  Güven Aslan; Bora Irer; Aykut Kefi; Ilhan Celebi; Kutsal Yörükoğlu; Adil Esen
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?

Authors:  Cavit Ceylan; Eymen Gazel; İbrahim Keleş; Ömer Doluoğlu; Metin Yığman
Journal:  Curr Urol       Date:  2016-02-10

Review 5.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 6.  Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Authors:  Alexander Haese; Markus Graefen; Hartwig Huland; Hans Lilja
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 3.092

Review 7.  Management of patients with an increasing prostate-specific antigen after radical prostatectomy.

Authors:  Masood A Khan; Alan W Partin
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.